【摘要】：糖尿病合并冠心病是在糖尿病基礎(chǔ)上由各種致病因素共同導(dǎo)致的心血管體統(tǒng)病變一種伴發(fā)癥或并發(fā)癥。在我國(guó)近年來(lái)隨著糖尿病的發(fā)病率越來(lái)越高,而糖尿病合并冠心病的發(fā)病率也逐步增加,嚴(yán)重影響了人民群眾的健康。中醫(yī)藥在對(duì)該病治療積累了很多經(jīng)驗(yàn),我們應(yīng)該挖掘中醫(yī)藥這個(gè)千年積累的寶庫(kù),從而找出新路。以減輕社會(huì)、患者家庭的經(jīng)濟(jì)負(fù)擔(dān),減少服藥種類,減輕服藥痛苦。冠心消渴安膠囊是杜廷海教授研制的既能治療糖尿病又能保護(hù)心血管的中成藥。希望通過(guò)本次動(dòng)物實(shí)驗(yàn)研究來(lái)印證冠心消渴安膠囊的藥效及藥用機(jī)理。目的:建立糖尿病合并性冠心病大鼠模型。觀察造模后大鼠模型心電圖及大鼠模型的冠脈和心肌組織的病理切片。通過(guò)試驗(yàn)觀察冠心消渴安膠囊對(duì)糖尿病冠心病大鼠模型空腹血糖(Fasting plasma glucose FPG)、空腹胰島素(Fasting insulin FINS)、胰島素敏感指數(shù)(Insulin sensitivity index ISI)、胰島素抵抗指數(shù)(Insulin resistance index IRI)、C反應(yīng)蛋白(C-reactive protein CRP)、白介素-6(Interleukin IL-6)水平的影響,驗(yàn)證冠心消渴安膠囊防治糖尿病合性冠心病療效,并初步探明藥用機(jī)理,為臨床用藥提供可靠的實(shí)驗(yàn)依據(jù)。方法:將大鼠用高脂飼料喂養(yǎng)后,用鏈脲佐菌素對(duì)大鼠進(jìn)行腹腔注射,建立糖尿病大鼠模型。在建立糖尿病大鼠模型后,給大鼠腹腔注射垂體后葉素注射液制備出糖尿病合并冠心病大鼠模型。通過(guò)對(duì)大鼠的心電圖、冠脈及心肌組織的病理切片的觀察來(lái)判定大鼠模型建立的結(jié)果。將制備好的模型分成空白對(duì)照組(A組)、模型對(duì)照組(B組)、二甲雙胍組對(duì)照組(C組)、冠心消渴安膠囊對(duì)照組(D組)。分組后開(kāi)始灌胃治療,空白對(duì)照組和模型對(duì)照組給予等量蒸餾水灌胃,二甲雙胍組灌胃二甲雙胍,冠心消渴安膠囊對(duì)照組灌胃冠心消渴安膠囊。末次灌胃后禁食24h不禁水,麻醉大鼠后,腹主動(dòng)脈取血分離血清。按照要求分別測(cè)定空腹血糖、空腹胰島素、C反應(yīng)蛋白、白介素-6含量根據(jù)大鼠空腹血糖、空腹胰島素計(jì)算出胰島素敏感指數(shù)、胰島素抵抗指數(shù)。取大鼠冠脈及心肌組織備用。結(jié)果:1.成功建立糖尿病合并冠心病大鼠模型。2.二甲雙胍對(duì)照組和冠心消渴安膠囊對(duì)照組與模型組對(duì)照組比較各項(xiàng)指標(biāo)均優(yōu)于模型對(duì)照組,且P0.05。在對(duì)大鼠模型空腹FINS,CRP,IL-6指標(biāo)的影響上,冠心消渴安膠囊對(duì)照組明顯優(yōu)于二甲雙胍對(duì)照組,P0.05。在對(duì)大鼠模型空腹FPG、IRI、ISI指標(biāo)的影響上,二甲雙胍對(duì)照組優(yōu)于冠心消渴安膠囊對(duì)照組,P0.05。結(jié)論:1.在糖尿病合并冠心病大鼠模型上,冠心消渴安膠囊和二甲雙胍降低FPG、IRI水平,提高了FINS、ISI水平。2.在糖尿病合并冠心病大鼠模型上,冠心消渴安膠囊和二甲雙胍都降低CRP、IL-6水平,冠心消渴安膠囊效果優(yōu)于二甲雙胍。
[Abstract]:Diabetes mellitus complicated with coronary heart disease (CHD) is a kind of cardiovascular disease which is caused by various pathogenic factors on the basis of diabetes mellitus. In recent years, with the increasing incidence of diabetes mellitus and coronary heart disease in China, the incidence of diabetes with coronary heart disease has gradually increased, which seriously affected the health of the people. Chinese medicine has accumulated a lot of experience in the treatment of this disease. In order to reduce the economic burden of society, patients' families, reduce the variety of medication, ease the pain of medication. Guanxin Xiaoke an capsule is a Chinese patent medicine developed by Professor du Tinghai to treat diabetes and protect cardiovascular system. It is hoped that the pharmacodynamics and medicinal mechanism of Guanxin Xiaokean capsule can be confirmed by this animal experimental study. Objective: to establish a rat model of diabetes mellitus with coronary heart disease (CHD). The electrocardiogram (ECG) of rat model and the pathological sections of coronary artery and myocardial tissue were observed. To observe the effect of Guanxinxiaokean capsule on fasting blood glucose (Fasting plasma glucose FPG), fasting insulin (Fasting insulin FINS), insulin sensitivity index (Insulin sensitivity index ISI), insulin resistance index (Insulin resistance index IRI) and C-reactive protein (C-reactive protein CRP), white) in diabetic coronary heart disease rats The effect of interleukin-6 (Interleukin IL-6) level, To verify the curative effect of Guanxinxiaokean capsule on diabetic coronary heart disease, and to explore the mechanism of medicine, and to provide reliable experimental basis for clinical use of drugs. Methods: the diabetic rat model was established by intraperitoneal injection of streptozotocin (STZ) after feeding with high fat diet. After the establishment of diabetic rat model, the rat model of diabetes with coronary heart disease was established by intraperitoneal injection of pituitrin injection. The results of rat model were determined by observing the pathological sections of electrocardiogram, coronary artery and myocardial tissue. The model was divided into three groups: blank control group (group A), model control group (group B), metformin group (group C) and Guanxinxiaokean capsule group (group D). The rats in the control group were given the same amount of distilled water, the metformin group was given the same amount of metformin, and the control group was given the Guanxin Xiaokean capsule. The rats were anesthetized after 24 hours fasting. Blood samples were taken from the abdominal aorta to separate the serum. Fasting plasma glucose, fasting insulin C-reactive protein and interleukin-6 were measured according to the requirements. The insulin sensitivity index and insulin resistance index were calculated according to fasting blood glucose and fasting insulin in rats. Coronary artery and myocardial tissue were taken from rats. The result is 1: 1. Successful establishment of diabetes mellitus with coronary heart disease rat model. 2. 2. The indexes of metformin control group and Guanxinxiaokean capsule control group were better than that of model control group (P0.05). The effect of Guanxinxiaokean capsule on fasting FINS,CRP,IL-6 in rat model was significantly better than that of metformin control group (P0.05). The effect of metformin on the fasting FPG,IRI,ISI index of rat model was better than that of Guanxin Xiaokean capsule control group (P0.05). Conclusion 1. In diabetic rats with coronary heart disease, Guanxinxiaokean capsule and metformin decreased the level of FPG,IRI and increased the level of FINS,ISI. 2. Both Guanxinxiaokean capsule and metformin decreased CRP,IL-6 level in diabetic rats with coronary heart disease, and the effect of Guanxin Xiaokean capsule was better than metformin.
【學(xué)位授予單位】：河南中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2016
【分類號(hào)】：R285.5;R-332

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 付旭彥,劉永紅;消渴安膠囊治療消渴(2型糖尿病)的臨床療效觀察[J];疑難病雜志;2002年04期

2 王智明,陳淑玉,周水平,夏世澄,龔明偉,李寶華,鄒如政,劉明樂(lè),安俊青;消渴安膠囊對(duì)2型糖尿病胰島素敏感性指數(shù)血脂的影響[J];中醫(yī)藥學(xué)刊;2004年01期

3 劉明樂(lè);李克榮;王智明;田怡;蘇大林;;消渴安膠囊制備工藝與臨床觀察[J];醫(yī)藥導(dǎo)報(bào);2008年04期

4 萬(wàn)宏;;消渴安膠囊的質(zhì)量研究[J];湖北中醫(yī)雜志;2012年01期

5 蘆長(zhǎng)海;消渴安膠囊治療糖尿病性下肢血管病變52例[J];中醫(yī)研究;1999年05期

6 覃俏峰;;消渴安膠囊和阿卡波糖對(duì)糖耐量減低患者空腹血糖及糖耐量的影響[J];中國(guó)醫(yī)藥導(dǎo)報(bào);2012年29期

7 陳寶生,呂久省,馮耀中,陳煥生;消渴安膠囊治療糖尿病性冠心病52例分析[J];國(guó)醫(yī)論壇;1997年03期

8 馬曉霖;消渴安膠囊治療糖尿病性冠心病的臨床研究[J];河南中醫(yī);1998年06期

9 杜廷海,呂小紅,呂靖中;消渴安膠囊治療糖尿病性冠心病150例臨床觀察[J];中國(guó)中醫(yī)藥科技;2001年02期

10 ;[J];;年期

相關(guān)會(huì)議論文 前3條

1 南征;南紅梅;何澤;;消渴安膠囊治療糖尿病(2型)920例臨床與實(shí)驗(yàn)研究[A];中華中醫(yī)藥學(xué)會(huì)內(nèi)科分會(huì)消渴病第五屆學(xué)術(shù)研討會(huì)論文集[C];2006年

2 郭寶榮;尹義輝;錢(qián)秋海;趙泉林;張娟;程益春;;消渴安膠囊治療糖尿病80例臨床研究[A];第四屆全國(guó)糖尿病（消渴�。⿲W(xué)術(shù)研討會(huì)論文集[C];1997年

3 呂靖中;杜廷海;呂小紅;;消渴安膠囊治療糖尿病性冠心病臨床觀察[A];糖尿�。ㄏ什。┲嗅t(yī)診治薈萃——全國(guó)第五次中醫(yī)糖尿病學(xué)術(shù)大會(huì)論文集[C];1999年

相關(guān)碩士學(xué)位論文 前3條

1 羅兵;冠心消渴安膠囊對(duì)糖尿病合并冠心病大鼠模型胰島素抵抗和炎性指標(biāo)的影響[D];河南中醫(yī)藥大學(xué);2016年

2 王麗;消渴安膠囊治療2型糖尿病脛前色素斑的臨床觀察[D];河南中醫(yī)學(xué)院;2015年

3 周文娟;冠心消渴安膠囊對(duì)糖尿病性冠心�。怅巸商摷骛鰺嶙C）的療效觀察和胰島素抵抗的影響[D];河南中醫(yī)學(xué)院;2015年

，

本文編號(hào)：2248110